Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes
Abstract
Treatment-emergent neuroendocrine prostate cancer (NEPC) after androgen receptor (AR) targeted therapies is an aggressive variant of prostate cancer with an unfavorable prognosis. The underlying mechanisms for early neuroendocrine differentiation are poorly defined and diagnostic and prognostic biomarkers are needed.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 21, 2022
- Source ID
- 10.1038/s43856-022-00182-9
Entities
People
- Ai-Ming Yu
- Alan P. Lombard
- Allen C Gao
- Amy R. Leslie
- Chengfei Liu
- Christopher P Evans
- Eva Corey
- Hong-Wu Chen
- Jinge Zhao
- Joy C. Yang
- Leandro S. D’Abronzo
- Masuda Sharifi
- Paramita M Ghosh
- Shu Ning
- Wei Lou
Organizations
- National Cancer Institute
- United States Army Medical Research Institute of Infectious Diseases
- United States Department of Health and Human Services
- United States Department of Veterans Affairs